Fei Jiang
Impact in
- Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- MicroRNA in disease regulation 16
- Cancer-related molecular mechanisms research 11
-
- Circular RNAs in diseases 12
- Co-authors
- Wenjie Zhang (13 shared papers)Xinquan Jiang (10 shared papers)Sihan Lin (9 shared papers)Guangzheng Yang (8 shared papers)Zhong Li (10 shared papers)Xiaobing Shen (11 shared papers)Yuan Li (7 shared papers)Yuezhi Lu (6 shared papers)
- Journals
- Advanced Materials (4 papers)Scientific Reports (4 papers)Journal of Molecular Histology (3 papers)Journal of Cellular and Molecular Medicine (3 papers)Journal of Medicinal Chemistry (3 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Fei Jiang
196 papers receiving 5.6k citations
Fei Jiang's Hit Papers
Peers
Comparison fields: 5 of 159
- Cancer Research 862
- Oncology 1.1k
- Biomaterials 517
- Urology 163
- Molecular Biology 1.9k
Countries citing papers authored by Fei Jiang
This map shows the geographic impact of Fei Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei Jiang more than expected).
Fields of papers citing papers by Fei Jiang
This network shows the impact of papers produced by Fei Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei Jiang. The network helps show where Fei Jiang may publish in the future.
Co-authors
The 25 scholars most cited alongside Fei Jiang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 215 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma Hit paper breakdown → | 2018 | 1296 |
| 2 | 2019 | 192 | |
| 3 | 2021 | 190 | |
| 4 | 2013 | 167 | |
| 5 | 2019 | 104 | |
| 6 | 2020 | 104 | |
| 7 | 2017 | 103 | |
| 8 | 2020 | 103 | |
| 9 | 2021 | 98 | |
| 10 | 2015 | 95 | |
| 11 | 2017 | 93 | |
| 12 | 2020 | 81 | |
| 13 | 2015 | 78 | |
| 14 | 2016 | 72 | |
| 15 | 2014 | 70 | |
| 16 | 2014 | 70 | |
| 17 | 2019 | 63 | |
| 18 | 2020 | 60 | |
| 19 | 2019 | 60 | |
| 20 | 2012 | 59 |
About Fei Jiang
Fei Jiang is a scholar working on Cancer Research, Molecular Biology, Biomaterials, Genetics and Immunology, having authored 215 papers that have together received 5.7k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (16 papers), Tissue Engineering and Regenerative Medicine (13 papers), Bone Tissue Engineering Materials (13 papers), Circular RNAs in diseases (12 papers), Cancer-related molecular mechanisms research (11 papers), Mesenchymal stem cell research (11 papers), interferon and immune responses (8 papers) and Electrospun Nanofibers in Biomedical Applications (7 papers). The work is most often cited by research in Cancer Research (862 citations), Oncology (1.1k citations), Biomaterials (517 citations), Urology (163 citations) and Molecular Biology (1.9k citations). Fei Jiang has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Wenjie Zhang, Xinquan Jiang, Sihan Lin, Guangzheng Yang, Zhong Li, Xiaobing Shen, Yuan Li, Yuezhi Lu, Shilong Ning and Xingxing Wang. Their work appears in journals such as Advanced Materials, Scientific Reports, Journal of Molecular Histology, Journal of Cellular and Molecular Medicine and Journal of Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.